Pinealon
Also called EDR; Glu-Asp-Arg
A three-amino-acid synthetic peptide studied as a "bioregulator." Laboratory work on stressed nerve cells is interesting, but it has not been shown to treat memory, sleep, or aging problems in people.
Overview
What it is
A tripeptide made of glutamic acid, aspartic acid and arginine. It belongs to the family of short peptides investigated by Russian bioregulator researchers. It is a different compound from Epitalon even though the two are often discussed together.
How it works
In cell studies, Pinealon reduced the build-up of reactive oxygen species and limited cell death under oxidative stress, and it changed some cell signaling. Separate lab work looked at how short peptides enter cell nuclei and interact with DNA. These are mechanism findings only; they do not show the peptide reaches the human brain or changes how a person thinks or sleeps.
What the research shows
Human data are limited to small Russian-language reports. One described changes in "biological age" scores among locomotive workers. Another, in older adults with several chronic conditions, reported some favorable measures alongside pro-oxidant activity and a drop in CD34-positive cell markers. Neither is strong enough to establish a reliable effect.
Studied for
- Oxidative stress in nerve cellslab
- Biological-age and adaptation scoressmall human reports
- Interest in sleep, memory and "brain fog"not established
Safety and regulatory status
Safety and side effects
The research record is too short to estimate how often side effects occur, which drug interactions matter, or whether repeated use is safe. The mixed findings in the small clinical report are a reason for more study, not reassurance. Product identity and purity add further uncertainty.
Regulatory status
Not approved by the FDA for any use.
Mixing and dosing reference
Reference information only. Read before using this section.
Pinealon (20 mg Vial) Dosage Protocol
- Vial
- 20 mg Pinealon
- Add diluent
- 3 mL
- Concentration
- 6.67 mg/mL
- 1 unit (U-100)
- 66.67 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous), preferably morning or early afternoon.
- Typical range
- 1.0–2.0 mg daily with gradual titration.
- Cycle length
- Standard 10–20 days; repeat cycles every 2–3 months.
Standard Approach
| Days | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Days 1–5 | 1.0 mg (1,000 mcg) | 15 units (0.15 mL) |
| Days 6–14 | 1.5 mg (1,500 mcg) | 22.5 units (0.225 mL) |
| Days 15–20 | 2.0 mg (2,000 mcg) | 30 units (0.30 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 1.0 mg daily for Days 1–5 to assess tolerance.
- Increase: 1.5 mg daily for Days 6–14.
- Target: 2.0 mg daily for Days 15–20 (or up to Day 28 if extending cycle).
- Frequency: Once per day (subcutaneous), preferably morning or early afternoon.
- Cycle Length: Standard 10–20 days; repeat cycles every 2–3 months.
- Timing: Consistent daily timing; rotate injection sites.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
Important notes
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Effects typically become noticeable after 10–14 days of consistent administration.
Protocol source: PeptideDosages.com
Common questions
Is Pinealon the same as Epitalon?
No. They are separate peptides with separate research. Results for one cannot be assumed for the other.
Is Pinealon the same as Semax or Selank?
No. Each has its own research record, and combining them has not been studied for safety.
Will it help sleep or brain fog?
The available studies did not measure those outcomes in a way that supports that claim. Ongoing sleep or memory problems deserve evaluation by a clinician.
Found in these blends
Related in Brain and Cognitive Health
Sources and further reading (6)
- PubChem. Glu-Asp-Arg (Pinealon) compound record.
- Khavinson V, et al. Pinealon increases cell viability by suppression of free radical levels. Rejuvenation Research, 2011.
- Fedoreyeva LI, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells. Biochemistry (Moscow), 2011.
- Biological-age and adaptation measures in locomotive workers. Advances in Gerontology, 2012.
- Meshchaninov VN, et al. Synthetic peptides and aging indicators in patients with chronic polymorbidity. Advances in Gerontology, 2015.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).